New Preclinical Data Shows Samaritan's Cardiovascular Drug Reduces Cholesterol; Cardiovascular Disease is a $15B Market Worldwi

Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of
innovative drugs, announced today, it has new preclinical data
gathered in a series of animal studies that shows its Cardiovascular
drug SP-1000 reduces blood cholesterol.
   Lowering cholesterol is a key component in the prevention and
management of heart disease. Earlier preclinical "in vitro" studies
gave Samaritan reason to believe its proprietary peptide SP-1000
cleans the blood of excessive cholesterol and corrects high
cholesterol conditions in people affected by the disease.
   Advancing to animal preclinical studies, SP-1000 data indicated
that it removes cholesterol from the LDL "bad"
cholesterol-apolipoprotein complex and it reduced blood cholesterol
levels in two different types of hypercholesterolemic "animal models."
These models included genetically engineered and diet-induced
hypercholesterolemic, animals. This new preclinical data is being
prepared to submit to a peer-reviewed journal.
   Dr. Greeson, CEO of Samaritan stated, "The novelty of SP-1000 as a
new cholesterol therapy lies in its 'mechanism of action,' that is
SP-1000 eliminates excessive cholesterol directly from the blood; in
contrast, to all known current cholesterol therapies where the
mechanism of action entails the enzymes responsible for cholesterol
synthesis in the liver. In addition, our drug comes at a time when
quite a few of the cholesterol lowering statins are about to come off
patent. We believe this is a drug that major pharmaceuticals will find
compelling, as well as the patients who have extreme difficulty
managing their cholesterol levels."

   Samaritan Pharmaceuticals: "We LIV....to Save Lives."

   Samaritan is a small-cap Biotech, driven to discover, develop, and
commercialize, innovative therapeutics for AIDS, Alzheimer's, cancer
and heart disease. Look at www.samaritanpharma.com. Please register on
Website so we can notify you of upcoming conference calls, news and
events.

   Disclaimer

   The company disclaims any information that is created by an
outside party and endorses only information that is communicated by
its press releases, filings and Website. This news release contains
forward-looking statements that reflect management's current beliefs
about the potential for its drug candidates, science and technology.
However, as with any biopharmaceutical under development, there are
significant risks and uncertainties in the process of development and
regulatory review. There are no guarantees that products will prove to
be commercially successful. For additional information about the
factors that affect the company's business, please read the company's
latest Form 10-K filed April 15, 2005. The company undertakes no duty
to update forward-looking statements.